Skip to main content
Vistin Pharma logo

Vistin Pharma — Investor Relations & Filings

Ticker · VISTN ISIN · NO0010734122 LEI · 5967007LIEEXZXFQY092 OL Manufacturing
Open in API
Filings indexed 519 across all filing types
Latest filing 2024-04-30 AGM Information
Country NO Norway
Listing OL VISTN

About Vistin Pharma

https://www.vistin.com/

Vistin Pharma is a pharmaceutical company specializing in the production of Metformin Hydrochloride, an Active Pharmaceutical Ingredient (API). The company operates as a pure-play, global supplier, providing high-quality Metformin to pharmaceutical companies worldwide. In addition to the standard API, Vistin Pharma offers specialized grades such as Direct Compressible (DC) Metformin. With over 50 years of experience, the company emphasizes sustainable manufacturing from its dedicated European production facility.

Recent filings

Filing Released Lang Actions
Vistin Pharma ASA: Notice of Annual General Meeting 23 May 2024
AGM Information Classification · 100% confidence The document text explicitly contains the phrases "INNKALLING TIL ORDINÆR GENERALFORSAMLING" (Norwegian) and "CALLING NOTICE FOR ANNUAL GENERAL MEETING" (English). It details the date (23. mai 2024), time, location, and the agenda for this meeting. This content directly corresponds to the definition of an Annual General Meeting (AGM) notice or presentation material. Therefore, the appropriate filing type code is AGM-R.
2024-04-30 English
Vistin Pharma ASA: Notice of Annual General Meeting 23 May 2024
Remuneration Information Classification · 98% confidence The document is explicitly titled 'Statement regarding the determination of salary and other remuneration to Executive Management' and details the principles, decision-making process, and components (fixed salary, bonus, pension, LTIP) for compensating the Board of Directors and Executive Management. This content directly aligns with the definition of a Remuneration Information document, which corresponds to the DEF 14A filing type in the provided schema, even though the document itself is a policy statement rather than the final report on paid remuneration. The text mentions that an annual report with an overview of paid remuneration shall be prepared, but the current document is the policy setting the framework for that remuneration. Given the options, DEF 14A (Remuneration Information) is the most specific fit for a detailed document outlining executive compensation policy and structure.
2024-04-30 English
Vistin Pharma ASA: Notice of Annual General Meeting 23 May 2024
AGM Information Classification · 98% confidence The document is titled 'Proposal from the Election Committee in Vistin Pharma ASA for the Annual General Meeting to be held in May 2024'. It details proposals regarding the re-election of Board members, the election of a former CEO as an observer, and the remuneration for the Board and Election Committee, all intended for approval at the upcoming Annual General Meeting (AGM). This content directly relates to the agenda and materials presented for the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R).
2024-04-30 English
Vistin Pharma ASA: Notice of Annual General Meeting 23 May 2024
Annual Report Classification · 100% confidence The document is titled 'Directors' report for 2023' and contains comprehensive financial statements, management discussion and analysis (MDA), operational performance reviews, and a sustainability report. It covers the full fiscal year 2023, providing detailed financial data, balance sheets, and cash flow statements. As it is a comprehensive annual report covering company activity and full financial performance for the year, it is classified as an Annual Report (10-K). FY 2023
2024-04-30 English
Vistin Pharma ASA: Notice of Annual General Meeting 23 May 2024
Annual Report Classification · 95% confidence The document is a detailed report covering the company's operating performance, financial results, strategy, organizational matters, and sustainability initiatives for the year 2023. It includes comprehensive financial data such as revenue, profit, cash flow, assets, equity, and investments. It also discusses events after the balance sheet date and provides a detailed sustainability report with ESG targets and investments. The presence of a Directors' report, detailed financial statements, and extensive narrative on business operations and outlook indicates this is a full annual report. There is no indication that this is merely an announcement or a summary; the length and depth confirm it is the actual report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-30 English
Vistin Pharma ASA: Notice of Annual General Meeting 23 May 2024
AGM Information Classification · 98% confidence The document explicitly states it is a 'Notice of Annual General Meeting 23 May 2024' and mentions that the formal call is 'attached to this announcement'. The content details the date, time, and procedure for the AGM, including proxy voting instructions. This strongly indicates materials related to the Annual General Meeting. Since it is the notice/call for the meeting itself, and not the voting results (DVA) or a general presentation (IP), the most appropriate classification is AGM Information (AGM-R). The document length is short (1336 chars), but the content is the core notice, not just an announcement that a report is available, making AGM-R more specific than RPA or RNS.
2024-04-30 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.